Annals of Oncology

Published by: Oxford University Press  

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Abou-Alfa
    Abou-Alfa
  4. O'Reilly
    O'Reilly
  5. Rosenberg
    Rosenberg
  6. Saltz
    Saltz
  7. Janjigian
    Janjigian
  8. Paik
    Paik
  9. Scher
    Scher
  10. Riely
    Riely

Groups

  1. Department of Medicine (1393)
  2. Solid Tumor Oncology Division (1292)
  3. Gastrointestinal Oncology Service (320)
  4. Genitourinary Oncology Service (301)
  5. Thoracic Oncology (277)
  6. GSK Faculty (193)
  7. Hematologic Malignancies, Division of (170)
  8. Survivorship Research (160)
  9. Breast Medicine Service (158)
  10. Center for Pancreatic Cancer Research (132)
Search Within
Formats
  1. Meeting Abstract (1227)
  2. Journal Article (372)
  3. Guidelines (19)
  4. Editorial (16)
  5. Review (16)
  6. Conference Paper (8)
  7. Correspondence (4)
  8. Research Letter (1)
Groups
  1. Department of Medicine (1393)
  2. Solid Tumor Oncology Division (1292)
  3. Gastrointestinal Oncology Service (320)
  4. Genitourinary Oncology Service (301)
  5. Thoracic Oncology (277)
  6. GSK Faculty (193)

More Groups

People
  1. Alexander Drilon (94)
  2. Robert Motzer (80)
  3. Ghassan Abou-Alfa (53)
  4. Matthew Hellmann (49)
  5. Eileen O'Reilly (48)
  6. Yelena Janjigian (44)

More People

Years
  1. 2025 (11)
  2. 2024 (147)
  3. 2023 (154)
  4. 2022 (158)
  5. 2021 (148)
  6. 2020 (152)

More Years

Publishers
  1. Oxford University Press (1663)

Results (1663)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reply to the letter to the editor by Perez et al. regarding “survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: A pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials”
    Correspondence

    Garcia-Aguilar, J.; Williams, H.; Fokas, E.; Rodel, C.
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: A pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials
    Journal Article

    Williams, H.; Fokas, E.; Diefenhardt, M.; Lee, C.; Verheij, F. S.; Omer, D. M.; Lin, S. T.; Dunne, R. F.; Marcet, J.; Cataldo, P.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: Final analysis of the phase III JAVELIN Renal 101 trial
    Journal Article

    Choueiri, T. K.; Penkov, K.; Uemura, H.; Campbell, M. T.; Pal, S.; Kollmannsberger, C.; Lee, J. L.; Venugopal, B.; van den Eertwegh, A. J. M.; Negrier, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Biomarker analyses from the phase III randomized CLEAR trial: Lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma
    Journal Article

    Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer
    Journal Article

    Chang, T. G.; Spathis, A.; Schäffer, A. A.; Gavrielatou, N.; Kuo, F.; Jia, D.; Mukherjee, S.; Sievers, C.; Economopoulou, P.; Anastasiou, M.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
    Journal Article

    Di Federico, A.; Hong, L.; Elkrief, A.; Thummalapalli, R.; Cooper, A. J.; Ricciuti, B.; Digumarthy, S.; Alessi, J. V.; Gogia, P.; Pecci, F.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 study
    Journal Article

    André, T.; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; Alcaide-Garcia, J.; Gibbs, P.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Locally advanced microsatellite instability-high esophagogastric cancer: Are we ready to change our treatment paradigm?
    Editorial

    Ilson, D. H.
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Anti-PD-1 treatment for MSI-H/MMRD tumors. A journey from genomics to transformative patient breakthroughs
    Editorial

    Argilés, G.; Arnold, D.; Cervantes, A.
    Annals of Oncology (2025)

    Fulltext@MSK | Save
  • Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
    Journal Article

    Rathkopf, D. E.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N.; Hawley, J. E.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K. D.; more...
    Annals of Oncology (2025)

    Fulltext@MSK | Save

    • Annals of Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Ann. Oncol. 0923-7534 Elsevier Inc.
    Annals of Oncology 15698041 Oxford University Press On Behalf of the European Society for Medical Oncology
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 09237534 Merck Sharp & Dohme Llc, A Subsidiary of Merck & Co., Inc., Rahway, Nj, Usa., The Author(s)
    Annals of Oncology 0923-7534 Unknown
    Annals of Oncology 09237534 Oxford University Press
    Annals of Oncology 15698041 Oxford University Press
    Annals of Oncology 09237534 The Author 2008
    Annals of Oncology 09237534 The Author 2013
    Annals of Oncology 09237534 The Author(s) 2018
    Annals of Oncology 09237534 The Author(s) 2019
    Annals of Oncology 0923-7534 Kluwer Academic Publishers
    Annals of Oncology 09237534 The Author 2007
    Annals of Oncology 09237534 Unknown
    Annals of Oncology 09237534 The Author
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 09237534 2024
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 09237534 The Author(s)
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 09237534 The Author 2016
    Annals of Oncology 09237534 The Author 2017
    Annals of Oncology 09237534 The Author 2011
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 09237534 2023
    Annals of Oncology 09237534 The Author 2012
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 09237534 The Author 2015
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 0923-7534 Elsevier Inc.
    Annals of Oncology 0923-7534 European Society for Medical Oncology
    Annals of Oncology 09237534 Kluwer Academic Publishers
    Annals of Oncology 0923-7534 Oxford University Press
    Annals of Oncology 09237534 The Authors
    Annals of Oncology 09237534 Oxford University Press On Behalf of the European Society for Medical Oncology
    Annals of Oncology 0923-7534 Oxford University Press On Behalf of the European Society for Medical Oncology
    Annals of Oncology 09237534 European Society for Medical Oncology
    Annals of oncology : official journal of the European Society for Medical Oncology 15698041 Oxford University Press On Behalf of the European Society for Medical Oncology
    Annals of oncology : official journal of the European Society for Medical Oncology 15698041 Unknown
    Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 15698041 Unknown